Abstract
Peroxisome proliferation-activated receptors (PPARs) are ligand-activated transcription factors that mainly regulate genes responsible for fatty acid (FA) and energy metabolism. There are three members of the PPAR family, PPAR-α, PPAR- β/δ and PPAR-γ. All three isoforms have therapeutic potential for treatment of cardiovascular disorders, and PPAR agonists are currently being actively studied in pre-clinical and clinical trials. PPAR γ agonists, main tissue expressing isoform, have potential to influence on inflammation processes, reduce oxidative stress, improve endothelial function and plays an important role in lipid metabolism. PPAR-γ agonists are used as insulin sensitizers for treatment of diabetes; however, there is accumulating evidence that their clinical application can be broadened. The wide spectrum of PPAR-γ activation effects may be beneficial for treatment of various cardiovascular conditions as atherosclerosis, hypertension and aortic aneurysm, including surgical interventions. In this Review we will discuss the implication of PPAR-γ in the cardiovascular system and potential role of PPAR-γ agonists in treatment of conditions associated with high cardiovascular risks.
Keywords: Peroxisome proliferation-activated receptor gamma (PPARγ), cardiovascular disorders, cardiovascular surgery, atherosclerosis.
Current Pharmaceutical Design
Title:Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis
Volume: 23 Issue: 7
Author(s): Ekaterina A. Ivanova, Veronika A. Myasoedova*, Alexandra A. Melnichenko and Alexander N. Orekhov
Affiliation:
- Unit of Atherosclerosis Prevention, Centro Cardiologico Monzino IRCCS, Via Carlo Parea 4, 20138, Milan,Italy
Keywords: Peroxisome proliferation-activated receptor gamma (PPARγ), cardiovascular disorders, cardiovascular surgery, atherosclerosis.
Abstract: Peroxisome proliferation-activated receptors (PPARs) are ligand-activated transcription factors that mainly regulate genes responsible for fatty acid (FA) and energy metabolism. There are three members of the PPAR family, PPAR-α, PPAR- β/δ and PPAR-γ. All three isoforms have therapeutic potential for treatment of cardiovascular disorders, and PPAR agonists are currently being actively studied in pre-clinical and clinical trials. PPAR γ agonists, main tissue expressing isoform, have potential to influence on inflammation processes, reduce oxidative stress, improve endothelial function and plays an important role in lipid metabolism. PPAR-γ agonists are used as insulin sensitizers for treatment of diabetes; however, there is accumulating evidence that their clinical application can be broadened. The wide spectrum of PPAR-γ activation effects may be beneficial for treatment of various cardiovascular conditions as atherosclerosis, hypertension and aortic aneurysm, including surgical interventions. In this Review we will discuss the implication of PPAR-γ in the cardiovascular system and potential role of PPAR-γ agonists in treatment of conditions associated with high cardiovascular risks.
Export Options
About this article
Cite this article as:
Ivanova A. Ekaterina, Myasoedova A. Veronika*, Melnichenko A. Alexandra and Orekhov N. Alexander, Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis, Current Pharmaceutical Design 2017; 23 (7) . https://dx.doi.org/10.2174/1381612823666161118145850
DOI https://dx.doi.org/10.2174/1381612823666161118145850 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pathophysiology of Coronary Thrombus Formation and Adverse Consequences of Thrombus During PCI
Current Cardiology Reviews Static Cerebral Blood Flow Autoregulation in Humans
Current Hypertension Reviews Update on the Imaging Techniques in the Diagnosis of Diabetic Retinopathy
Current Diabetes Reviews Preoperative and Follow up Multi-Detector Row CT Angiography (MDCTA) in the Evaluation of Interrupted Aortic Arch (IAA)
Current Medical Imaging Atherosclerosis as an Inflammatory Disease
Current Pharmaceutical Design High-pitch Dual-source CT Angiography before TAVI - the Value of ECG Gating
Current Medical Imaging Protein/Polyphenol Interactions: Past and Present Contributions. Mechanisms of Astringency Perception
Current Organic Chemistry Involvement of Leukotriene Pathway in the Pathogenesis of Ischemia- Reperfusion Injury and Septic and Non-Septic Shock
Current Vascular Pharmacology Propofol and Systemic Inflammatory Response in Abdominal Aortic Surgery
Letters in Drug Design & Discovery RAAS Inhibition and Cardiorenal Syndrome
Current Hypertension Reviews The Shift in the “Paradigm” of the Pharmacology of Hypertension
Current Topics in Medicinal Chemistry Hemothorax
Current Respiratory Medicine Reviews Portal Vein Embolization: A Preoperative Approach to Improve the Safety of Major Hepatic Resection
Current Medical Imaging The Possibility of Novel Antiplatelet Peptides: The Physiological Effects of Low Molecular Weight HSPs on Platelets
Current Pharmaceutical Design Role of COL4A1 in Basement-Membrane Integrity and Cerebral Small-Vessel Disease. The COL4A1 Stroke Syndrome
Current Medicinal Chemistry Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio as Biomarkers for Cardiovascular Surgery Procedures: A Literature Review
Reviews on Recent Clinical Trials Vascular Stiffness: Measurements, Mechanisms and Implications
Current Vascular Pharmacology Heart Failure in Acute Ischemic Stroke
Current Cardiology Reviews Genetic Determinants of Cerebral Arterial Adaptation to Flow-loading
Current Neurovascular Research 3D CT Angiography of Infrarenal Abdominal Aortic Aneurysm with Associated Ectopic Pelvic Kidney: A Case Report of Rare Concomitance
Current Medical Imaging